ARCA biopharma retains Ladenburg Thalmann for strategic options review

Oruka Therapeutics, Inc.

Retained Ladenburg Thalmann & Co. Inc. as financial advisor for strategic review.
Board formed Special Committee in April 2022 to explore value-maximizing alternatives.
Potential alternatives include acquisition, merger, business combination, or other transaction.
No timetable set for review; no assurance that any transaction will result.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.